Kiros Tadele G, Power Carl A, Wei Guojian, Bretscher Peter A
Vaccine & Infectious Diseases Organization, University of Saskatchewan, Saskatoon, Saskatchewan, Canada.
Immunotherapy. 2010 Jan;2(1):25-35. doi: 10.2217/imt.09.80.
Neonatal bacille Calmette-Guerin (BCG) vaccination is widely employed to protect against tuberculosis. Predominant Th1 but not mixed Th1/Th2 responses are thought to be protective. If so, effective vaccination must cause Th1 imprints. The immune system of infants differs from that of adults and such differences could critically affect neonatal vaccination. We demonstrate that BCG infection of infant and adult mice produces similar responses. Infection with low and high numbers of BCG, respectively, leads to sustained Th1 and mixed Th1/Th2 responses. Low-dose but not high-dose infection also results in Th1 imprints, guaranteeing a Th1 response upon high-dose challenge, and resulting in optimal bacterial clearance. Our observations on low-dose Th1 imprinting are intriguing in the context of the well-known madras trial. In this trial, the highest dose of BCG, which had insignificant side effects, was administered to over 250,000 human subjects. This high-dose vaccination resulted in insignificant protection against tuberculosis.
新生儿卡介苗(BCG)接种被广泛用于预防结核病。主要的Th1反应而非混合的Th1/Th2反应被认为具有保护作用。如果是这样,有效的疫苗接种必须引起Th1印记。婴儿的免疫系统与成人不同,这种差异可能会严重影响新生儿疫苗接种。我们证明,婴儿和成年小鼠感染卡介苗会产生相似的反应。分别用低剂量和高剂量的卡介苗感染,会导致持续的Th1反应和混合的Th1/Th2反应。低剂量而非高剂量感染也会导致Th1印记,保证在高剂量攻击时产生Th1反应,并导致最佳的细菌清除。在著名的马德拉斯试验背景下,我们对低剂量Th1印记的观察结果很有趣。在该试验中,对超过25万名受试者接种了副作用不明显的最高剂量卡介苗。这种高剂量疫苗接种对结核病的保护作用不明显。